NeutralLOW severityHealthcare & Pharma1h ago

Martine Rothblatt, United Therapeutics CEO, sells $5.5M in stock

Martine Rothblatt, United Therapeutics CEO, sells $5.5M in stock — $UTHR one-month chart
$UTHR daily closes over the past month · Wook of Wall Street artwork from market data
WOOK’s read

United Therapeutics shares hit a session high of $587.50, up 0.46%, near the top of its 52-week range. The stock is trading at 89% of its range, with coverage steady and neutral in tone, and no recent bullish signals. Earnings are due in 11 days, and the Health Care sector shows calm today.

Written by Wook AI Oct 24, 3:34 AM ET from this page’s own figures at that time — not from the article — with every number checked against them. Not investment advice.

WOOKAI ASSISTANTREADY
WOOK AIASK ANYTHING · NEVER ADVISES

Meet Wook AI, your friendly assistant. Ask how something works, about any company, fund or coin, or have it do the math — live figures come from this site’s own lookups, and you’ll see which ones it used.

Wook analysis

What it means

Key points
  • What to watch: This one turns on a concrete figure ($5); set it against the recent trend before reading it as a turning point.
  • How the stock is trading: $UTHR +0.46% in the latest session.
  • Timing: Weekend news: the change beside it is Friday's, and Monday's open is the first session that gets a say. Market holidays are not detected.
Amount$5.5 million

Where the stock stands

$UTHR last changed hands at $587.50, +0.46% on the session, 3.6% below its 52-week high of $609.35 and 44% above its low of $409.07 — in the upper part of the range. Over the year it has ranged 49% from low to high: a moderate band — lively, not wild. These are latest-session quotes, not live prices — the live tape is on the $UTHR page.

How much coverage it is getting

In the last 30 days Wook has filed 7 stories about $UTHR — 1 of them this week. At its 30-day pace you would expect about 2 a week, so this week is quieter than usual. Across those stories the wording ran 0% bullish, 100% neutral and 0% bearish. This one reads neutral, so it sits squarely with the crowd. 7 of the 7 (100%) came from Investing.com itself, so the count says as much about how often Investing.com hits publish as about how much attention there is — the other outlets are the better gauge. 12 of them are listed beside this one.

The bigger picture

In healthcare, the calendar is the catalyst — trial readouts, FDA decisions and pricing rules. One result can move a single drugmaker sharply; a policy change moves the whole aisle. Wook's supply-chain scanner has Health Care reading calm today: no unusual stress in the filings and disclosures it watches.

Coming up

$UTHR earnings in 11 days. These were on the calendar before this story and are not caused by it, but the nearest is close enough that the next hard numbers on this company are almost here.

What to watch next

For the receipts, the $UTHR page has the full chart, the filings and the valuation model these figures come from. Because one outlet dominates the coverage, reading another outlet on the same story is the quickest check on whether it is being confirmed or just repeated. And Wook AI, up top, will happily do the math — how far $UTHR sits from its high, or how this week's coverage stacks up.

How this analysis was made

Investing.com published it, and Wook filed it under Healthcare & Pharma. No strongly worded term either way, so it reads neutral at low severity — a factual headline rather than a charged one. It was matched to $UTHR. It carried $5.5 million, shown as published and not recalculated. The publisher gave no preview text, and nothing has been written in to fill the gap.

The tone and severity labels come from a fixed word list — no editor, no AI, no crystal ball — so they describe how a story is worded, not what happens next. They are not a forecast or a recommendation, and a same-day move does not mean this story caused it. Not investment advice.

Discussion

No one has weighed in yet. Start the discussion on this story.

Headline and link are attributed to Investing.com. Wook of Wall Street is an independent research tool and is not affiliated with Investing.com. Nothing here is financial advice or a recommendation — research and educational content only.